Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
about
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsImpact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis.Treatment options for venous thromboembolism: lessons learnt from clinical trials.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Warfarin and atrial fibrillation: from ideal to real the warfarin affaire.Management of venous thromboembolism--controversies and the future.Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.Effective practical management of patients with atrial fibrillation when using new oral anticoagulants.Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.Safety of non-vitamin K antagonist oral anticoagulants - coronary risks.The use of direct oral anticoagulants in inherited thrombophilia.Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.Dabigatran and myocardial infarction: a foggy scenarioDirect thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
P2860
Q26781181-879F2DF2-396C-4EFC-B0C4-7265B89BD0CDQ34343826-65E9E3E4-0B63-4C02-8744-838D1C1D5BB6Q34694544-96BD22F0-7009-4D5F-80A0-D2C7FD42C256Q35683869-9B1266FC-C39A-4F1C-BBD1-869DC810DBACQ37607493-EF56EE36-551E-45A5-AC43-ED24C9291DFCQ38093286-65FCA99A-2CD5-4695-9101-9F6B5F4B0C41Q38218292-232F26C7-A350-49DD-997B-7FFB4F0E8725Q38409730-CB14B73F-E979-4DD3-8313-ED5C66E5D463Q38602280-2C06E936-60B7-4252-86E8-DB35F447BBCDQ38766678-E5935A33-5117-46B8-9EFB-12329238C2F5Q38979239-982FA0B2-B2EE-4039-8A87-E1111799FD42Q38991392-3C1B0FEE-26E2-4938-802E-40AF757005E1Q42651838-F14A4B89-8806-44CB-8735-13DBAF62FB84Q42734808-DC5D035F-F657-46DE-A4B1-26EF876A9051Q43092928-CC786095-0E7C-4645-9F57-1A848C94F5C8Q47449437-383715D0-EA78-48A3-9578-E461B131EF95
P2860
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Coronary and mortality risk of ...... is of large randomised trials.
@ast
Coronary and mortality risk of ...... is of large randomised trials.
@en
type
label
Coronary and mortality risk of ...... is of large randomised trials.
@ast
Coronary and mortality risk of ...... is of large randomised trials.
@en
prefLabel
Coronary and mortality risk of ...... is of large randomised trials.
@ast
Coronary and mortality risk of ...... is of large randomised trials.
@en
P2860
P1433
P1476
Coronary and mortality risk of ...... is of large randomised trials.
@en
P2093
Koon-Hou Mak
P2860
P356
10.1136/BMJOPEN-2012-001592
P577
2012-10-06T00:00:00Z